


# ELISA-VIDITEST CXCL13



## VIDIA new immunoenzymatic kits

- for the quantitative determination of chemokine CXCL13 in cerebrospinal fluid.


... the way to  
the correct  
results



Short  
detection time



High specificity  
and sensitivity



Automatic  
processing



Accurate LNB  
diagnostics

### Diagnosis of spirochetal neuroinfections

**Neuroborreliosis is a form of Lyme disease (LNB) affecting the central and peripheral nervous system (CNS).** It is caused by an infection with *Borrelia burgdorferi sensu lato* due to a tick bite. The diagnosis of neuroborreliosis is based on the patient's medical history, clinical signs of infection, serum and cerebrospinal fluid (CSF) analysis, and serological evidence of borrelia antibodies. **Chemokine ligand 13 (CXCL13) plays an important role in diagnosis as an accurate, highly sensitive diagnostic biomarker of early-stage neuroinfection.**

### Benefits of the kits

- Accurate and rapid diagnosis of Lyme euroborreliosis
- Determination of CXCL13 level/concentration
- Aimed at urgent examinations



### ELISA-VIDITEST

**Kits come from our own research, development and production.**


We are VIDIA spol s r. o. Czech biotechnological company with a wide range of kits for diagnostic examination. We develop our products with high quality.

# ELISA-VIDITEST CXCL13


CXCL13 (chemokine ligand 13), also known as B-cell attracting chemokine 1 (BAC-1) or B-cell chemoattractant (BLC), is a member of the CXC chemokine family. CXCL13 is produced by dendritic cells, monocytes and mature macrophages. It activates the cellular immune response after binding to a specific G-receptor, CXCR5. It specifically stimulates B-lymphocytes and controls their migration from lymphoid tissues to the site of inflammation, especially into the cerebrospinal fluid (CSF). **CXCL13 is thus a key modulator of CNS inflammation. It appears to be of important clinical importance for the diagnosis and monitoring of Lyme neuroborreliosis (LNB) and other**

**neuroinfections. CXCL13 is expressed at high levels in the CSF of patients with early-stage LNB.** Elevated CXCL13 concentrations correlate better with pleocytosis than with AI positivity. Patients with late-subacute neuroinfection occasionally show positive AI and low CXCL13 levels. CXCL13 levels decline rapidly after initiation of treatment. **The ELISA-VIDITEST kit has a high sensitivity and specificity for the quantitative detection of the biomarker CXCL13 in cerebrospinal fluid.** The kit provides quick information on CXCL13 levels in patients with symptoms of neuroinfection. CXCL13 level determination can also be used to differentiate between active and regressive LNB stages.

## Test principle and the procedure step by step




## Benefits of the measurement

- Quantitative evaluation of biomarker CXCL13
- Quick information on CNS inflammation
- Diagnosis and monitoring of LNB and other neuroinfections
- Sample: cerebrospinal fluid
- High diagnostic specificity and sensitivity
- Color-coded r.t.u. reagents
- Manual/automatic processing in the analyzer 



## VIDIA kits



REF	Product	Evaluation	Incubation	Sample	Number of tests	VIDIMAT
ELISA-VIDITEST						
ODZ- 510	CXCL-13	quant.	60' / 60' / 60' / 15'	cerebrospinal fluid	96	✓ 



**VIDIA spol. s r.o.**  
Nad Safinou II 365, 252 50 Vestec  
Czech Republic

tel.: +420 261 090 565  
fax: +420 261 090 566

e-mail: info@vidia.cz  
www.vidia.cz

